Abstract
Background/Aims: Tyrosine phosphorylation of the EPIYA motif in Helicobacter pylori CagA (CagA-P) plays an important role in toxic reaction. Diffuse-type gastric cancer (DGC) has a poor prognosis. We tried to clarify the expression level of CagA-P in DGC patients. Methods: We enrolled 42 early-stage DGC patients (DGC group; 20 males, 22 females, mean age 58.2 years) and 42 age- and gender-matched atrophic gastritis (AG) patients (AG group) as controls. We evaluated histological and serological gastritis and examined two markers; the serum titer of anti-CagA-P antibody and CagA-P expression in gastric mucosa. Results: In the DGC group, we found significantly higher corpus histological gastritis scores for activity, atrophy, and intestinal metaplasia. The titer of anti-CagA-P antibody and CagA-P expression in the corpus were significantly higher in the DGC group, especially in females (p < 0.05). Sixteen patients (38.1%) in the DGC group showed both positive markers, and the odds ratio for DGC occurrence was 4.00 (95% CI = 1.07–14.91), while that for females was 9.00 (95% CI = 1.29–62.97). Conclusions: CagA-P plays a role in active corpus gastritis, which may link to DGC carcinogenesis. Clinical quantification of CagA-P-related markers may be useful for the evaluation of DGC risk, especially in females.
Journal Section:
Original Paper
References
1.
Suzuki H, Hibi T, Marshall BJ: Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 2007;42:1–15.
[PubMed]
2.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
[PubMed]
3.
Haruma K, Komoto K, Kamada T,Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G: Helicobacter pylori is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol 2000;35:255–259.
[PubMed]
4.
Hatakeyama M, Higashi H: Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci 2005;96:835–843.
[PubMed]
5.
Backert S, Ziska E, Brinkmann V, Zimny-Arndt U, Fauconnier A, Jungblut PR, Naumann M, Meyer TF: Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus.Cell Microbiol 2000;2:155–164.
6.
Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683–686.
[PubMed]
7.
Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4:688–694.
[PubMed]
8.
Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, Hatakeyama M: Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 2002;99:14428–14433.
[PubMed]
9.
Azuma T, Yamakawa A, Yamazaki S, Fukuta K, Ohtani M, Ito Y, Dojo M, Yamazaki Y, Kuriyama M: Correlation between variation of the 3′ region of the cagA gene in Helicobacter pylori and disease outcome in Japan. J Infect Dis 2002;186:1621–1630.
[PubMed]
10.
Ueda H, Ito M, Eguchi H, Tanaka S, Yoshihara M, Haruma K, Hatakeyama M, Chayama K: Development of a novel method to detect Helicobacter pyloricagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. Digestion 2006;73:47–53.
[PubMed]
11.
Xie XF, Ito M, Sumii M, Tanaka S, Yoshihara M, Chayama K: Helicobacter pylori-associated gastritis is related to babA2 expression without heterogeneity of the 3′ region of the cagA genotype in gastric biopsy specimens. Pathobiology 2007;74:309–316.
[PubMed]
12.
Takata S, Ito M, Wada Y, Yoshihara M, Tanaka S, Chayama K: Pathogenetic role of the tyrosine-phosphorylated CagA EPIYA sequence of Helicobacter pylori in histological gastritis in Japanese patients. J Gastroenterol 2009;44:405–411.
[PubMed]
13.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston, 1994. Am J Surg Pathol 1996;20:1161–1181.
[PubMed]
14.
Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, Komoto K, Tanaka S, Kajiyama G: Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998;93:1090–1096.
[PubMed]
15.
Ito M, Haruma K, Kaya S, Kamada T, Kim S, Sasaki A, Sumii M, Tanaka S, Yoshihara M, Chayama K: Role of anti-parietal cell antibody in Helicobacter pylori-associated atrophic gastritis: evaluation in a country of high prevalence of atrophic gastritis. Scand J Gastroenterol 2002;37:287–293.
[PubMed]
16.
Goto T, Haruma K, Kitadai Y, Ito M, Yoshihara M, Sumii K, Hayakawa N, Kajiyama G: Enhanced expression of inducible nitric oxide synthase and nitrotyrosine in gastric mucosa of gastric cancer patients. Clin Cancer Res 1999;5:1411–1415.
[PubMed]
17.
Parsonnet J, Friedman GD, Orentreich N, Vogelman H: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297–301.
[PubMed]
18.
Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M: Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008;105:1003–1008.
[PubMed]
19.
Yoshihara M, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, Haruma K: Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol 2007;42:760–764.
[PubMed]
20.
Oka S, Tanaka S, Kaneko I, Mouri R, Hirata M, Kawamura T, Yoshihara M, Chayama K: Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006;64:877–883.
[PubMed]
21.
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392–397.
[PubMed]
22.
Miyamoto M, Haruma K, Yoshihara M, Sumioka M, Nishisaka T, Tanaka S, Inoue K, Chayama K: Five cases of nodular gastritis and gastric cancer: a possible association between nodular gastritis and gastric cancer. Dig Liver Dis 2002;34:819–820.
[PubMed]
23.
Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Talley NJ: Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol 1998;93:1271–1276.
[PubMed]
24.
Hatakeyama M: Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009;44:239–248.
[PubMed]
25.
Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Mémet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL: Nod1 responds to peptidoglycan delivered by the Helicobacter pyloricag pathogenicity island. Nat Imuunol 2004;5:1166–1174.
[PubMed]
26.
Sasao S, Hiyama T, Tanaka S, Yoshihara M, Yasui W, Chayama K: Clinicopathologic and genetic characteristics of gastric cancer in young male and female patients. Oncol Rep 2006;16:11–15.
[PubMed]
27.
Kato S, Matsukura N, Toqashi A, Masuda G, Matsuda N, Yamada N, Naito Z, Matsuhisa T, Tajiri T: Sex differences in mucosal response to Helicobacter pylori infection in the stomach and variations in interleukin-8, COX-2 and trefoil factor family 1 gene expression. Aliment Pharmacol Ther 2004;20:17–24.
[PubMed]
28.
Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M: Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. Shock 2001;16:340–343.
[PubMed]
29.
Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, Takamura A, Kitamura S, Matsuo T, Tanaka S, Haruma K, Chayama K: Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 2009;44:365–371.
[PubMed]
30.
Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simöes M: E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001;20:1525–1528.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
